LoadingLoadingLoading22 funds hold it.Insiders net selling.
Net selling: insiders sold $289K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsLast report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.65 expected
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Jun 30, 2026Reported Aug 4, 2026 | $0.73est. $0.65 | +12.79%beat | $192.4MSEC filing | +6.2%from $181.1M |
| Mar 31, 2026Reported Apr 30, 2026 | $0.60est. $0.56 | +6.41%beat | $177.4MSEC filing | +5.0%from $168.9M |
| Dec 31, 2025Reported Feb 26, 2026 | $0.57est. $0.90 | -36.98%miss | $196.9MAlpha Vantage | +5.1%from $187.3M |
| Sep 30, 2025Reported Nov 6, 2025 | $0.70est. $0.65 | +7.44%beat | $179.5MSEC filing | +6.5%from $168.6M |
| Jun 30, 2025Reported Aug 5, 2025 | $0.74est. $0.71 | +4.23%beat | $181.1MSEC filing | +1.7%from $178.0M |
| Mar 31, 2025Reported May 8, 2025 | Not on file | No estimate | $168.9MSEC filing | +1.1%from $167.1M |
| Dec 31, 2024Reported Feb 27, 2025 | $0.91est. $0.83 | +9.60%beat | $187.3MAlpha Vantage | +3.3%from $181.2M |
| Sep 30, 2024Reported Nov 6, 2024 | $0.79est. $0.70 | +12.86%beat | $168.6MSEC filing | +2.8%from $163.9M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $179.5M | $196.9M | $177.4M | $192.4M |
| Cost of what it sold | $34.3M | $40.3M | $36.4M | $44.2M |
| Gross profit | $145.2M | $156.6M | $141.0M | $148.2M |
| What it spent | ||||
| Research and development | $26.0M | $37.5M | $28.1M | $30.2M |
| Sales and admin | $33.3M | $40.0M | $35.8M | $91.8M |
| Other operating costs | $79.6M | $75.9M | $72.5M | $21.9M |
| Total operating expenses | $138.9M | $153.4M | $136.3M | $144.0M |
| What was left | ||||
| Operating profit | $6.4M | $3.2M | $4.6M | $4.3M |
| Interest on debt | $3.7M | $3.4M | $3.2M | $3.6M |
| Profit before tax | $9.5M | $571.0K | $5.0M | $2.6M |
| Tax | $4.1M | -$1.1M | $2.1M | -$2.1M |
| Net profit | $5.4M | $1.6M | $2.9M | $4.7M |
| EBITDA | $34.4M | $25.3M | $29.5M | $25.6M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
22 macro signals shaping PCRX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
